Chemistry:Rostafuroxin
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
21,23-Epoxy-24-nor-5β-chola-20,22-diene-3β,14β,17-triol
| |
| Systematic IUPAC name
(1S,3aS,3bR,5aR,7S,9aS,9bS,11aS)-1-(Furan-3-yl)-9a,11a-dimethylhexadecahydro-3aH-cyclopenta[a]phenanthrene-1,3a,7-triol | |
| Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
| UNII | |
| |
| Properties | |
| C23H34O4 | |
| Molar mass | 374.521 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Tracking categories (test):
Rostafuroxin is a digitoxigenin analog that has been shown to lower blood pressure in an animal model of hypertension.[1] It modulates the effects of the enzyme Na+/K+-ATPase,[1] which maintains sodium and potassium ion gradients across plasma membranes. Rostafuroxin is being studied in clinical trials for the treatment of essential hypertension.[2][3]
References
- ↑ 1.0 1.1 Ferrari, Patrizia; Ferrandi, Mara; Valentini, Giovanni; Bianchi, Giuseppe (2006). "Rostafuroxin: An ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 290 (3): R529–R535. doi:10.1152/ajpregu.00518.2005. PMID 16467500.
- ↑ Ferrari, Patrizia (2010). "Rostafuroxin: An ouabain-inhibitor counteracting specific forms of hypertension". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1802 (12): 1254–1258. doi:10.1016/j.BBAdis.2010.01.009. PMID 20083196.
- ↑ "Efficacy of Rostafuroxin in the Treatment of Essential Hypertension". clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT00415038.
 |  |
